Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2

Int J Infect Dis. 2021 Dec:113:233-235. doi: 10.1016/j.ijid.2021.09.066. Epub 2021 Sep 29.

Abstract

The ongoing vaccination program in the control of novel coronavirus (COVID-19)is providing an opportunity to public health authorities to emerge from the current pandemic crisis.Covid vaccination which protects from getting Covid may have some minor side effects and in rare cases was accompanied by severe or immediate reactions. The development of hyaluronic acid soft tissue filler delayed inflammatory reactions following COVID-19 vaccination was reported. Treatments based on hyaluronic acid represent one of the most largely used practice of aesthetic medicine. In this we present a case of a 38-year-old female patient with a confirmed hypersensitivity reaction after having the BNT162b2 vaccine (Pfizer, USA). This case indicates that an adequate patient knowledge prior to hyaluronic acid injections to avoid adverse effect of a delayed-type hypersensitivity response after COVID-19 vaccination is desirable.

Keywords: COVID-19; Dermal filler; Hyaluronic acid; Hypersensitivity response; SARS-CoV-2; Vaccination.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Dermal Fillers*
  • Female
  • Humans
  • Hyaluronic Acid / adverse effects
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines
  • Dermal Fillers
  • Hyaluronic Acid
  • BNT162 Vaccine